Medical Marijuana, Inc. (OTC Pink: MJNA) operates as a medical cannabis production and distribution company. Shares of the medical cannabis company are rallying 5.56%, through early trading on Thursday, November 2, 2017. Over the past month, Medical Marijuana, Inc. has seen average daily volume of 6.8 million shares. However, volume of 4.33 million shares or dollar volume of $368,483, has already exchanged hands on the day.
Shares of Medical Marijuana, Inc. are gaining today, after the company announced that general manager of HempMeds Mexico subsidiary, Raul Elizalde, was interviewed on Azteca TV Mexico regarding global CBD policy and benefits. In addition, Mr. Elizalde will be delivering a speech to the World Health Organization Drug Scheduling Convention on Psychotropic Substances on November 6, 2017. Here is the full press release detailing of the interview:
Medical Marijuana, Inc. Press Release:
SAN DIEGO, Nov. 2, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that Raúl Elizalde, General Manager of subsidiary HempMeds® Mexico, was recently interviewed on Azteca TV Mexico, resulting in notable media coverage of his upcoming speaking engagement at the World Health Organization Drug Scheduling Convention on Psychotropic Substances on November 6, 2017.
According to the interview, Elizalde explained that “The World Health Organization will address cannabidiol along with a list of other substances that they are analyzing to know if they need to be updated and scheduled as psychoactive substances. Cannabidiol is not psychoactive and we wonder how cannabidiol ended up in a list of substances with some synthetic ones like ketamine and vigabatrin.” He later went on to say that “part of what I’m going to do at the World Health Organization is to talk to them and explain that cannabidiol has no side effects and that there is a difference [between CBD and marijuana].”
“We couldn’t be more enthusiastic about Raúl representing the Medical Marijuana, Inc, portfolio of companies and our mission to further access of CBD on such a large global stage,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We are optimistic that he will help the World Health Organization and the United Nations see that botanical CBD derived from hemp should be viewed as a nutritional supplement.”
This speaking opportunity has the capacity to positively impact the recommendation that the World Health Organization will give to the United Nations on how CBD should be scheduled. Substance policy is largely influenced by the United Nations and if CBD is scheduled as a drug, this could severely limit the global access of it.
About HempMeds® Mexico
HempMeds®Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company’s website at: http://www.hempmeds.mx
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
The statements in this press release have not been evaluated by the Food and Drug Administration (FDA) and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.